Dr. William Hearl is the founder & CEO of Immunomic Therapeutics, Inc. and is an experienced and successful life science businessman and entrepreneur. Dr. Hearl is adept at brokering mutually beneficial partnerships and identifying non-traditional collaborations and investment opportunities, highlighted by his groundbreaking $300 million deal with Astellas Pharma in 2015. Dr. Hearl has been active in the Maryland biotech community for over 30 years. In 2000, he founded of Capital Genomix, Inc., a Maryland-based biomarker and drug discovery Company. Prior to CGI he served in various roles at other Maryland – based companies including Kirkegaard & Perry Laboratories (KPL), Life Technologies, IGEN and Pharmacia – Electro-Nucleonics. Dr. Hearl earned his Ph.D. in biochemistry from the University of Tennessee and B.S. from East Tennessee State University.